青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床研究  

Artesunate united Primaquine in the treatment of delay or reconnection malaria

作　　者：孙卫华[1] Afel TRAORE 

机构地区：[1]浙江省嘉兴市第一医院医务科 [2]Hospital of Markala

出　　处：《中国临床药理学与治疗学》2011年第1期98-100,共3页Chinese Journal of Clinical Pharmacology and Therapeutics

摘　　要：目的:探讨青蒿琥酯联用伯氨喹治疗迁延、复燃疟疾的临床疗效。方法:将82例患者随机分成治疗组和对照组各41例。治疗组:给予青蒿琥酯和伯氨喹:青蒿琥酯首剂2.4 mg/kg i.v.,12 h后予1.2 mg/kg青蒿琥酯,随后6 d每日以1.2 mg/kg青蒿琥酯同法给予;同时加服伯氨喹片22.5 mg q.d.。对照组:给予quini max,首剂20 mg/kg,i.v.gtt,12 h后予10 mg/kg,随后每日12 h给予10 mg/kg,直至患者能口服,改口服quini max片10 mg/kg,q.8.h,疗程7 d。结果:7 d后治疗组、对照组治愈率分别为97.5%、95.1%;28 d治疗组、对照组治愈率分别为97.5%、90.2%,治疗组与对照组变化相近(P>0.05);两组的退热时间分别为28.0、51.6 h,血中疟原虫清除时间分别为30.4、59.5 h,治疗组较对照组均降低(P<0.01)。结论:青蒿琥酯联用伯氨喹治疗疟疾作用迅速,副作用小,低复燃率,且对耐奎宁株有效,可作为迁延、复发疟疾以及用奎宁等传统抗疟药治疗失败的首选方法。AIM ： To approach the clinical therapeutic effects of artesunate united Primaquine in the treatment of delay or recrudescence malaria. METHODS ： 82 patients were randomly divided into two groups.Patients of the treatment group（n =41）were given an initial dose of 2.4 mg/kg artesunate i.v.,12 h later,a second dose of 1.2 mg/kg artesunate was given in the same way.For the succeeding 6 days,a daily dose of 1.2 mg/kg artesunate was given in the same manner to each patient in the treatment group;and each of the patients were given Primaquine tables 22.5 mg/d,p.o..The control group（n =41）were given an initial dose of 20 mg of quinimax i.v.,12 h later,a second dose of 10 mg/kg quinimax was given in the same way.Thereafter,10 mg/kg of quinimax was given q.12.h.In the same manner until the patients could take medicines by mouth.Quinimax tablets in a dose of 10 mg/kg were then given q.8.h.The course of treatment was 7 d. RESULTS ：After 7 and 28 d,the cure rates in the treatment and control group were 97.5 %,95.1 %;97.5 %,90.2 %,respectively.The changes in the treatment and control group were similar（P 0.05）.The defervescence time was 28.0 and 51.6 h,and the clearing time of haemoplasmodium was 30.4 and 59.5 h in the treatment and control group,respectively;the differences was significant（P 0.01）. CONCLUSION ： Artesunate united Primaquine was found to act more quickly in the treatment of pernicious delay or recrudescence malaria,low recurrence rate,with only mild side effects.It is also effective in the treatment of malaria caused by quinine-resistant strains of malaria parasites.It should be the drug of first choice in the treatment of malaria that quinine fails to effect a cure.

关 键 词：青蒿琥酯 伯氨喹 QUINIMAX 疟疾 

分 类 号：R978.61[医药卫生—药品]